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Abstract
Purpose The purpose of our study is to determine if there
is a relationship between dose deposition measured by
PET/MRI and individual lesion response to yttrium-90
(90Y) microsphere radioembolization.
Materials and Methods 26 patients undergoing lobar
treatment with 90Y microspheres underwent PET/MRI
within 66 h of treatment and had follow-up imaging
available. Adequate visualization of tumor was available in
24 patients, and contours were drawn on simultaneously
acquired PET/MRI data. Dose volume histograms (DVHs)
were extracted from dose maps, which were generated
using a voxelized dose kernel. Similar contours to capture
dimensional and volumetric change of tumors were drawn
on follow-up imaging. Response was analyzed using both
RECIST and volumetric RECIST (vRECIST) criteria.
Results A total of 8 hepatocellular carcinoma (HCC), 4
neuroendocrine tumor (NET), 9 colorectal metastases
(CRC) patients, and 3 patients with other metastatic disease
met inclusion criteria. Average dose was useful in pre-
dicting response between responders and non-responders
for all lesion types and for CRC lesions alone using both
response criteria (p\ 0.05). D70 (minimum dose to 70 %
of volume) was also useful in predicting response when
using vRECIST. No significant trend was seen in the other
tumor types. For CRC lesions, an average dose of 29.8 Gy
offered 76.9 % sensitivity and 75.9 % specificity for
response.
Conclusions PET/MRI of 90Y microsphere distribution
showed significantly higher DVH values for responders
than non-responders in patients with CRC. DVH analysis
of 90Y microsphere distribution following treatment may
be an important predictor of response and could be used to
guide future adaptive therapy trials.
Keywords Radioembolization  Dosimetry 
Imaging  PET  Liver/hepatic  Cancer
Introduction
Radioembolization of hepatic malignancies delivers higher
radiation dose to tumors than surrounding liver par-
enchyma [1–6]. This is achieved by selective injection of a
high-energy radiation source, 90Y [Yttrium-90, 0.93 MeV;
tissue penetration mean 3.9 mm, maximum 11 mm], into
the hepatic artery supplying the lobe or region of the tumor.
The typical pre-procedure work-up includes diagnostic
imaging with contrast-enhanced computed tomography
(CT) or magnetic resonance imaging (MRI) to determine
tumor burden, angiography to identify anomalies that may
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lead to non-target embolization, and evaluation for hep-
atopulmonary shunting via technetium-99m-labeled
macroaggregated albumin (99mTc-MAA) injection with
SPECT/CT [6, 7]. While generally well tolerated, the main
complications of radioembolization are liver toxicity from
radiation exposure and non-target embolization [8–15].
Response is generally heterogeneous between patients,
even those with the same tumor types [16, 17].
Because of the importance of selective delivery and
adequate dose to tumor coverage, there is growing interest
in quantitatively and qualitatively imaging 90Y micro-
spheres within the liver after delivery. Historically, post-
therapy imaging was done with Bremsstrahlung imaging
[18, 19]; however, positron emission tomography (PET)
has generally replaced SPECT due to the need for higher
resolution imaging to localize dose distribution [18–29]. In
a recent study focusing on hepatocellular carcinoma
patients, Lea et al. demonstrated wide variation in mea-
sured tumor and parenchymal doses on PET/CT following
lobar administration of glass microspheres [30]. This wide
variability may lead to heterogeneous tumor response and
the potential to under-dose tumors while over-dosing
background liver [27, 31]. The authors suggested the need
for continued patient-specific dosimetry methods.
The purpose of our study was to assess the feasibility of
PET/MRI to evaluate the 90Y microsphere deposition and
the resultant dose delivered in individual lesions. The
second purpose was to assess whether the measured dose
was related to local tumor response. To our knowledge, this
is the first series of 90Y PET/MRI patients published with
clinical follow-up.
Materials and Methods
Patient Sample
Between October 1, 2012 and April 17, 2014, patients
undergoing radioembolization for any indication were
recruited and consented on an IRB-approved protocol
(NCT01744054) for PET/MRI imaging on a Siemens
Biograph mMR (Siemens Healthcare, Erlangen, Germany).
26 of these patients had imaging follow-up as defined as
contrast-enhanced imaging at 3 months or later. Two
patients were excluded from analysis due to inability to
confidently draw contours around their initial lesion or
lesion on follow-up imaging, leaving 24 patients for this
analysis. Patient demographics, treatment details and tumor
characteristics are listed in Table 1. All patients underwent
90Y microsphere delivery pretreatment evaluation and
delivery according to standard procedures. Two patients
received whole liver treatment as opposed to standard lobar
treatment to prevent further delay of chemotherapy.
Current methods for prescribing radioembolization dose,
as recommended by the manufacturer [6], differ in part by
the particle type (resin versus glass). Glass microsphere
(TheraSpheres, BTG International, Canada) dose pre-
scription is determined by the following equation:
Infused liver volume (independent of tumor burden)
A GBqð Þ ¼ Ddesired Gyð Þ Mtargetliver kgð Þ
 
=50
These microspheres are typically delivered to patients
with unresectable hepatocellular carcinoma (HCC) and
occasionally metastatic neuroendocrine tumors (NET).
Resin microspheres (SIR-spheres, Sirtex Medical Ltd.,
Sydney, Australia) may be administered by body surface
area method:
BSA and % tumor burden
A GBqð Þ ¼ BSA  0:2þ % tumor involvement=100ð Þ:
These microspheres are typically delivered to metastatic
lesions in the liver, such as colorectal cancer (CRC) and
NET. These methods also require estimation of a lung
shunt fraction prior to treatment with reduction in dose if
the lung shunt fraction is above 10–20 %. The average
activity delivered to patients was 1.65 GBq (range:
0.4–4.96 GBq), which correlates to a dose of
120–130 Gy in the treated lobe of the liver. An inherent
limitation of the current strategies for estimating dose is the
assumption of uniform delivery within the segment,
section, or lobe to which radioactivity is delivered.
Post-treatment 90Y PET/MRI Acquisition
Parameters
Post-procedural PET/MRI consisted of routine liver
sequences (detailed below) and simultaneous PET data
acquisition. The PET component consists of 8 rings of 56
detector blocks, each with a 4 9 4 9 20 mm LSO (lute-
tium oxyorthosilicate) crystals with scintillation light
readout using avalanche photodiodes. The coincidence
window time resolution is 5.86 ns. The spatial resolution is
4.3 mm (reconstructed resolution closer to 6 mm) at
FWHM. Imaging was done within 66 h (range 0.75–66 h)
of 90Y radioembolization based on patient and scanner
convenience.
Patients were positioned with arms raised, and
20–40 min of PET data were acquired in a single station to
cover the liver and lower thorax. The MR sequences used
were a 2-point DIXON for attenuation correction, T2
Turbo spin-echo (TSE) fat-suppressed axial respiratory
navigated, in/opposed-phase dual-echo gradient recall T1-
weighted, pre-contrast volumetric interpolated breath hold
examination (VIBE), dynamic post-contrast VIBE, coronal
post-contrast VIBE, diffusion-weighted images (b values
50, 400, 800), axial non-fat-suppressed T2-weighted, radial
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free-breathing VIBE, and a 20-min delayed VIBE in the
axial and coronal planes (for gadoxetic acid enhanced MRI
only). Intravenous contrast consisted of gadoxetic acid
(Bayer Pharmaceuticals; dose of 0.05 mmol/kg) adminis-
tered at 1 ml/second or gadobenate dimeglumine (Multi-
hance, Bracco Diagnostics; dose of 0.1 mmol/kg)
administered at 2 ml/second.
90Y PET/MR Reconstruction Parameters
Tomographic images were generated by iterative recon-
struction [3D-Ordered Subset Expectation Maximization
(OSEM)] using the following parameters for the Siemens
Biograph mMR: 3 iterations, 21 subsets, 172 9 172
matrix, post-processing Gaussian filter of 5 mm in full
width at half maximum, and with point spread function
compensation, resulting in a voxel size of
4.17 9 4.17 9 2.02 mm. The parameters for reconstruc-
tion were based upon phantom studies conducted at our
institution to determine the optimal recovery coefficient
with a moderate noise level over a wide range of activity
levels [33]. Attenuation correction was derived from the
2-point DIXON MR VIBE sequence (TR = 3.6 ms,
TE1 = 2.46 ms and TE2 = 1.23 ms, flip angle of 10).
Scatter correction was applied using a single scatter sim-
ulation technique as provided by the manufacturer. The
attenuation of the PET caused by the bed and fixed MRI
coils was automatically integrated into the attenuation
Table 1 Patient demographics and treatment information
Patient demographics
Tumor
type
Age and
gender
#Tumors correspond
to follow-up
Total tumor
volume(cc)
Delivery site (glass or
resin microspheres)
Delivered
activity (GBq)
Contrast agent
for PET/MRI
HCC
83, F 1 61.78 Left lobe (resin) 0.7 Eovist
83, F 1 5.0 Right lobe(resin) 1.03 Eovist
75, F 1 1514.3 Left lobe (glass) 2.99 Eovist
61, M 1 157.7 Whole liver (glass) 3.94 Eovist
77, M 1 185.0 Left lobe (glass) 2.21 Eovist
62, M 1 549.0 Left lobe (glass) 1.09 Eovist
74, M 3 376.7 Right lobe (glass) 4.96 Multihance
73, F 1 27.7 Left lobe (glass) 0.82 Multihance
NET
52, M 9 623.6 Right lobe (glass) 2.2 Eovist
40, M 6 21.0 Right lobe (glass) 0.4 Eovist
75, M 2 494.6 Left lobe (resin) 0.9 Multihance
48, F 8 27.7 Right lobe (resin) 0.7 Multihance
CRC
52, M 1 257.8 Right lobe (resin) 1.6 Eovist
59, M 2 2393.3 Right lobe (resin) 1.4 Eovist
57, M 3 212.1 Right lobe (resin) 0.9 Eovist
82, F 2 73.0 Right lobe (resin) 1.0 Eovist
68, M 4 100.2 Whole liver (resin) 3.2 Eovist
60, F 10 223.2 Right lobe (resin) 1.0 Multihance
53, M 3 40.9 Right lobe (resin) 1.6 Multihance
48, M 12 1681.2 Right lobe (resin) 1.5 Multihance
54, M 5 356.7 Right lobe (resin) 2.0 Multihance
Esophageal
63, M 3 326.4 Right lobe (resin) 1.6 Multihance
Breast
57, F 3 39.1 Right lobe (resin) 1.0 Multihance
Thymic carcinoid
49, M 4 529.1 Left lobe (resin) 0.9 Multihance
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maps. The scanner was calibrated for absolute activity
concentration using a 20 cm diameter 68Ge cylinder con-
taining a known activity concentration and cross-calibrated
to the laboratory dose calibrator with a similarly configured
18F-filled cylinder. Since 90Y was not a listed nuclide for
PET acquisition on the Siemens Biograph mMR scanner,
we used the settings of 86Y for data acquisition and image
reconstruction. The scanner calibration factor (ECF) used a
ratio of the positron fractions between the selected isotope
for scanning (86Y) and 68Ge, and then we manually cor-
rected for 90Y by scaling the reconstructed image intensity
by the relative b ? decay branching ratios and decay
constants of 86Y and 90Y. Our previous phantom study with
90Y chloride solution showed that the calibration from 68Ge
was accurate [33].
Image Evaluation and Post-processing
PET and MRI data were reviewed on MimVista (MIM
Software, Cleveland, OH) by a board-certified, fellowship-
trained MRI radiologist (10 years of experience in
abdominal imaging), using rigid registration to align and
fuse the liver boundaries. MR sequences were co-regis-
tered, and tumor contours, lobar, and whole liver contours
were drawn primarily on the Gadoxetic hepatobiliary phase
images (20 min delay) or on arterial or portal venous
images for patients who received an alternate contrast
agent. Images were assessed qualitatively for expected
distribution of dose based on injection site and extrahepatic
deposition. Regions of interest were drawn over the para-
spinal muscles to derive a background value. Dose maps
were calculated by convolution of the activity concentra-
tion images from 90Y PET images and a voxelized radia-
tion dose kernel [34]. In short, images were re-sampled on
3-mm cubic voxels, convolved with MIRD-17 3D 3 mm
voxel dose-point kernel, and finally re-sampled on the
original voxel size, similar to Lea et al. [30]. Image pro-
cessing was performed using an application written in
MATLAB R2012a (Mathworks, Natick, MA). Voxel resi-
dence times were calculated using immediate uptake and
physical decay only. Based upon the PET-generated dose
maps, dose volume histograms (DVH), which plot the
minimum dose (Gy) to a given volume (%) of a specified
region of interest, were generated for each lesion measur-
ing C1 cm diameter for RECIST criteria and C1 cc for
vRECIST criteria. Smaller lesions were not analyzed due to
inability to confidently draw contours and identify the
lesions on follow-up imaging. To determine treatment
response, follow-up imaging was acquired on all patients
according to standard of care intervals. Contours were
drawn around the same lesions as contoured on the initial
imaging time point (with initial and follow-up imaging
assessed in the same session to allow accurate matching).
Standard RECIST criteria were used for differentiating
responders (C30 % decrease in the longest tumor diame-
ter), non-responders (C20 % increase in the longest tumor
diameter), and stable lesions (else) [35]. A separate anal-
ysis using volumetric RECIST (vRECIST) was also used to
differentiate responders ([65 % decrease in tumor volume)
from non-responders (\65 % decrease in tumor volume or
progression).
Statistical Analysis
Summary metrics, including the individual lesion volumes,
minimum dose to 20 % of the lesion (D20), minimum dose
to 70 % of the lesion (D70), and average dose (Davg),
between responders and non-responders were assessed
using a two-sample t test and logistic regression. Results
were considered statistically significant at p\ 0.05. Dose
thresholds for assessing response were obtained using
receiver operating characteristic (ROC) analysis to deter-
mine sensitivity and specificity for response.
Results
All patients tolerated the imaging procedure without
adverse event, and the total time from beginning to end of
the PET/MR examination ranged from 42 to 60 min. The
fusion of PET and MRI data was accomplished with ade-
quate registration in all cases using rigid registration. The
distribution of 90Y microspheres was concordant to injec-
tion site in all patients (treated lobe:background SUVmean
ratios were significantly greater than 1 for all patients
(p\ 0.001). A single case of extrahepatic deposition was
identified due to a patent falciform artery. The patient
developed no adverse event related to the deposition. No
patients had significant toxicity following 90Y radioem-
bolization treatment.
Response Analysis Based on RECIST
Using standard RECIST criteria, there were 38 responding
lesions, 46 stable lesions, and 8 non-responding lesions
across the 24 patients. The relationship of DVH and
response is shown in Fig. 1. Davg and D70 were statistically
significant in predicting response between responders and
non-responders (p\ 0.05, see Table 2). Davg was statisti-
cally significant in predicting response between responders
and stable lesions (p\ 0.05, see Table 2); however, D70
was not statistically significant for this response pair
(p[ 0.05, see Table 2). No statistical significance was
achieved for predicting response between non-responders
and stable lesions (p[ 0.05, see Table 2). In an effort to
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control for any confounding effects, there was no correla-
tion between response and tumor size (p[ 0.05). Within
individual patients, there was heterogeneous response of
lesions to treatment (see Fig. 2A).
Figure 3 shows the relationship of DVH and response
for CRC patients (n = 9 patients, 43 lesions). Davg between
responders and non-responders was the only quantity that
achieved statistical significance for predicting response for
the CRC lesions (p\ 0.05, see Table 2).
Figure 4 shows the relationship of DVH and response
for hypervascular lesions (HCC, NET, and thymic carci-
noid; n = 13 patients; 42 lesions). There was no significant
Fig. 1 Dose volume histograms of all lesions color-coded by
response as defined by RECIST. Gy Gray. Davg and D70 are
significant for predicting response between responding (green) and
non-responding (red) lesions (p = 0.0092 and 0.0063, respectively)
Table 2 Factors associated with RECIST response on univariate analysis
RECIST p values from logistic regression analysis All lesions CRC lesions Hypervascular lesions
Average Dose D70 Average dose D70 Average dose D70
Response/progression 0.0092* 0.0063* 0.0452* [0.05 [0.05 [0.05
Response/stable 0.0291* [0.05 [0.05 [0.05 [0.05 [0.05
Progression/stable [0.05 [0.05 [0.05 [0.05 [0.05 [0.05
*Significance achieved at p\ 0.05
Fig. 2 Patient with colorectal
carcinoma (CRC) metastases to
the liver showing heterogeneous
lesion response following lobar
treatment. The DVH shows a
mix of responders and
stable disease, according to
RECIST (A), and responders
and non-responders, according
to vRECIST (B). The PET/MR
fused image (C) demonstrates
the contours of different lesions
at baseline as well as the
overlay of the 90Y microsphere
deposition within the treated
lobe. Follow-up imaging
(D) shows the change in lesion
size
Fig. 3 Dose volume histograms of colorectal metastases (CRC)
color-coded by response as defined by RECIST. Davg is significant for
predicting response between responding (green) and non-responding
(red) lesions (p = 0.0452)
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relationship between DVH values and response due to the
low number (n = 3) of non-responding lesions. A single
HCC lesion represents one of a few outliers in the data and
is shown in Fig. 5 along with the DVH for the lesion.
Despite relatively high delivered dose, the lesion did not
demonstrate decrease in size and remained primarily
enhancing at follow-up imaging acquired 87 days follow-
ing treatment.
Response Analysis Based on vRECIST
Using vRECIST, there were 64 responding lesions and 23
non-responding lesions across the 24 patients. The rela-
tionship of DVH and response is shown in Fig. 6. Both
Davg and D70 achieved statistical significance in predicting
response (p\ 0.05, see Table 3). Within individual
patients, there was heterogeneous response of lesions to
treatment (see Fig. 2B).
Figure 7 shows the relationship between DVH and
response for CRC lesions using vRECIST criteria. Across
the 9 patients, there were 25 responding lesions and 17
non-responding lesions. Both Davg and D70 achieved sta-
tistical significance for predicting response, with equal p
values (p\ 0.05, see Table 3). For CRC lesions, a Davg of
29.8 Gy provided 76.9 % sensitivity and 75.9 % specificity
for predicting response; D70 of 42.3 Gy provided 61.5 %
sensitivity and 96.6 % specificity for predicting response.
Figure 8 shows the relationship between DVH and
response for hypervascular lesions using vRECIST criteria.
Similar to standard RECIST, these lesions did not achieve
statistical significance in predicting response (p[ 0.05, see
Table 3).
Discussion
There is growing interest in imaging the delivered activity
following 90Y radioembolization both for confirmation of
delivery site and quantification of dose [26, 27, 36]. PET
imaging appears to be the most reliable and best option,
providing higher spatial resolution and more accurate
depiction of uptake than 90Y Bremsstrahlung SPECT
imaging [26, 38]. In our study, PET/MR imaging of 90Y
microsphere distribution demonstrated similar quantitative
and qualitative results as previously published with PET/
CT, including the ability to discern extrahepatic deposition
[23, 25, 37].
In our study, the DVH was generated to measure dose
distribution within tumors. This method has previously
Fig. 4 Dose volume histograms of hypervascular lesions (HCC,
NET, thymic carcinoid) color-coded by response as defined by
RECIST. There were no summary statistics that were significant
enough to predict response between any of the response categories
(p[ 0.05, see Table 2)
Fig. 5 Hepatocellular
carcinoma (HCC) lesion
representing one of the three
outliers among the
hypervascular lesions (see
Fig. 4). Despite a relatively high
delivered dose (A), this lesion
did not respond to therapy. PET/
MRI (B) shows expected
deposition. Baseline MRI
(C) and follow-up MRI (D)
show stable/no response as
defined by RECIST/vRECIST
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been shown to correlate with tumor response [27]; how-
ever, the exact metric Davg or D70 remains controversial
[40]. When using vRECIST, our results for CRC patients
were significant for Davg and D70 metrics; however, sta-
tistical significance was not achieved for D70 when using
standard RECIST. Using ROC analysis, we were also able
to demonstrate a threshold for vRECIST response in CRC
patients at Davg = 29.8 Gy (sensitivity 76.9 %; specificity
75.9 %) and D70 = 42.3 Gy (sensitivity 61.5 %; specificity
96.6 %).
Although RECIST is the standard method for assessing
lesion response, Tacher et al. recently found that vRECIST
was a more accurate predictor of patient survival following
transcatheter arterial chemoembolization (TACE) [39]. In
our study, we correlated dosimetric quantities with
response using both response criteria. Both RECIST and
vRECIST resulted in statistically significant results for
predicting response across all lesions and for CRC lesions.
There was a greater significance achieved using vRECIST
as opposed to RECIST for CRC lesions. While vRECIST
results were stronger, the average dose was still statistically
significant in predicting response between responding and
non-responding lesions when using RECIST. Stable dis-
ease or disease control, while not the primary goal of
therapy, may be a reasonable outcome and was considered
as a separate category. Neither vRECIST nor RECIST
measurements demonstrated statistical significance in dif-
ferentiating this category from responders and non-
responders.
The inherent value of DVH analysis is that it captures
the heterogeneous nature of 90Y microsphere deposition.
Prior studies have shown wide variations in measured
tumor and parenchymal 90Y microsphere deposition fol-
lowing lobar administrations [25, 30]. In a recent study,
Padia et al. showed heterogeneous 90Y microsphere depo-
sition within tumor and portal vein tumor thrombus that
appeared to correlate with regions of necrosis on follow-up
imaging [25]. Srinivas et al. demonstrated wide variability
in dose delivered to 98 HCC lesions [41]. The concept of
Fig. 6 Dose volume histograms of all lesions color-coded by
response as defined by vRECIST. Davg and D70 are significant for
predicting response between responding (green) and non-responding
(red) lesions (p = 0.0341 and 0.0194, respectively)
Table 3 Factors associated with vRECIST response on univariate analysis
vRECIST p values from logistic regression analysis All lesions CRC lesions Hypervascular lesions
Average dose D70 Average dose D70 Average dose D70
Response/progression 0.0341* 0.0194* 0.0004* 0.0004* [0.05 [0.05
* Significance achieved at p\ 0.05
Fig. 7 Dose volume histograms of colorectal metastases (CRC)
color-coded by response as defined by vRECIST. Davg and D70 are
significant for predicting response between responding (green) and
non-responding (red) lesions (p = 0.0004)
Fig. 8 Dose volume histograms of hypervascular lesions (HCC,
NET, thymic carcinoid) color-coded by response as defined by
vRECIST. There were no summary statistics that were significant
enough to predict response between any of the response categories
(p[ 0.05, see Table 3)
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heterogeneous delivery to the parenchyma and tumors may
explain heterogeneous response of different lesions within
patients who have large tumor burden, as was seen in our
study (Fig. 2-CRC patient). It is possible that distribution
of 90Y microspheres within the target area is highly
dependent on locoregional flow factors, injection rate,
proximity and complexity of daughter vessel branching,
particle load, and cardiovascular dynamics, in addition to
inherent tumor vascularity and necrosis. Most current
dosing models assume uniform delivery of activity to the
treated region/tumor, which is likely a false assumption.
Our study confirms the variable dose distribution and is the
first to show significant relationship between the DVH in
CRC metastases and response of the lesions on follow-up
imaging.
The results of our study represent the first dose–response
database generated by PET/MR DVH data for CRC
patients undergoing radioembolization treatment. Future
adaptive trials may implicate the findings of post-treatment
PET/MRI to achieve adequate tumor coverage. Chang et al.
published preliminary data suggesting that quantitative
PET/CT following 90Y radioembolization treatment in
HCC could achieve more optimized dose coverage (in-
crease in 40 Gy absorbed dose to tumor) and ultimately a
complete response [42].
Our study failed to show a similar significant DVH:re-
sponse relationship in hypervascular lesions (HCC and
NET primarily). In the series published by Srinivas et al.,
the authors likewise failed to show significant correlation
between the mean tumor dose and response in 48 evaluable
lesions (21 responders, 27 non-responders) [41]. While
their results did not reach significance, there was a trend
toward greater response and higher dose. Other authors
have demonstrated positive correlation. Kao et al. reported
retrospective dose–response information using PET/CT
post-treatment DVH analysis, suggesting that complete
response could be achieved in HCC patients with a
D70[ 100 Gy and that this dose level was achieved more
easily in smaller tumors (\80 cm3) [27]. The lack of sig-
nificance in our population may be explained by the outlier
HCC case and also the small population size. Further
research is needed to confirm the positive results shown by
others.
There are several limitations of our study. The
dose:response data generated represent that acquired on a
lesion by lesion basis, which are of great value; however,
ultimately patient outcomes and overall survival are better
metrics of treatment efficacy. It is our hope that our pre-
liminary results may inform future larger prospective trials
with overall survival as the final outcome measure. Another
limitation is imperfect registration. While PET/MRI is
acquired in a simultaneous manner, improved registration
through motion correction algorithms are needed to
advance the technological aspects of the study. We were
able to achieve satisfactory registration in all cases using
MimVista non-deformable registration. Furthermore, in our
phantom study and in other phantom studies on PET/CT,
recovery for regions 8-37 mm in diameter is only about
50 % for 90Y compared to what is recovered when mea-
suring with 18F [32, 43]. Even though point spread function
(PSF) compensation was included in the reconstruction
process, which has been shown to improve contrast
recovery and mitigate partial volume effects in PET images
[44], counts were still not completely recovered in the
reconstructed 90Y PET images from ours and other’s
phantom studies [33, 41]. Further work with partial volume
correction is needed for improving quantitative accuracy,
especially for smaller lesions.
Although the results of PET/MR occur after radioem-
bolization, this does not reduce the clinical utility. Imme-
diate predictions (i.e., not waiting for the follow-up
imaging study, which usually does not occur for 3 months
following therapy) of tumor response could stratify patient
therapy based on lesion prognosis. We would hope that this
prediction of response could guide further liver directed or
systemic therapies, such as cryoablation, microwave abla-
tion, stereotactic radiation, or changes in chemotherapy.
Our results provide preliminary data suggesting that PET/
MRI and volumetric tumor measurements (vRECIST) may
provide a useful metric for predicting response in CRC
patients.
In conclusion, simultaneous PET/MR imaging is a fea-
sible way of determining 90Y microsphere distribution in
the liver. Additional work to improve the quantitative
nature of this imaging modality is needed. Future clinical
and research applications may yield improvements in
radioembolization delivery, dosing, and response
assessment.
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